CORXEL Pharmaceuticals
Financing Round
- Series D
Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative small molecule therapies for cardiometabolic diseases and acute ischemic stroke, with lead clinical programs in oral GLP-1 therapy for obesity and type 2 diabetes and a thrombolytic/anti-inflammatory agent for acute ischemic stroke.
View Website
Modality
- Small Molecule
Indication
- Circulatory & Metabolic Disease
Development Status
- Phase 2